SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size 2/07/13 Unitedhealth Group Inc 10-K 12/31/12 114:25M |
Document/Exhibit Description Pages Size 1: 10-K Annual Report HTML 1.52M 2: EX-10.11 Material Contract HTML 38K 3: EX-10.32 Material Contract HTML 78K 4: EX-10.33 Material Contract HTML 82K 5: EX-10.36 Material Contract HTML 104K 6: EX-10.37 Material Contract HTML 35K 8: EX-21.1 Subsidiaries List HTML 229K 9: EX-23.1 Consent of Experts or Counsel HTML 34K 10: EX-24.1 Power of Attorney HTML 43K 7: EX-12.1 Statement re: Computation of Ratios HTML 47K 11: EX-31.1 Certification -- §302 - SOA'02 HTML 50K 12: EX-32.1 Certification -- §906 - SOA'02 HTML 38K 78: R1 Document and Entity Information Document HTML 62K 63: R2 Condensed Consolidated Balance Sheets HTML 164K 74: R3 Condensed Consolidated Balance Sheet HTML 69K (Parenthetical) (Parentheticals) 82: R4 Condensed Consolidated Statements of Operations HTML 125K 104: R5 Condensed Consolidated Statements of Comprehensive HTML 92K Income 65: R6 Condensed Consolidated Statements of Changes in HTML 109K Shareholders' Equity 73: R7 Condensed Consolidated Statements of Cash Flows HTML 173K 57: R8 Description of Business HTML 38K 47: R9 Basis of Presentation HTML 206K 106: R10 Investments HTML 270K 84: R11 Fair Value HTML 336K 83: R12 Property, Equipment, and Capitalized Software HTML 59K 90: R13 Goodwill and Intangible Assets HTML 140K 91: R14 Medical Costs and Medical Costs Payable HTML 70K 88: R15 Commercial Paper and Long-Term Debt HTML 216K 92: R16 Income Taxes HTML 158K 75: R17 Shareholder's Equity HTML 65K 79: R18 Share-Based Compensation HTML 119K 86: R19 Commitments and Contingencies HTML 58K 114: R20 Segment Financial Information HTML 307K 100: R21 Quarterly Financial Data (Unaudited) HTML 82K 69: R22 Schedule I HTML 195K 85: R23 Basis of Presentation (Policy) HTML 185K 71: R24 Fair Value Fair Value Policy (Policies) HTML 50K 38: R25 Income Taxes Income Tax (Policies) HTML 44K 101: R26 Shareholder's Equity Shareholder's Equity HTML 48K (Policies) 110: R27 Share-Based Compensation Recognition (Policies) HTML 52K 52: R28 Segment Financial Information Segment Financial HTML 43K Information (Policies) 51: R29 Basis of Presentation Basis of Presentation HTML 75K (Tables) 55: R30 Investments (Tables) HTML 268K 56: R31 Fair Value (Tables) HTML 324K 58: R32 Property, Equipment, and Capitalized Software HTML 58K Property, Equipment, and Capitalized Software (Tables) 27: R33 Goodwill and Intangible Assets Goodwill and HTML 141K Intangible Assets(Tables) 98: R34 Medical Costs and Medical Costs Payable Medical HTML 72K Cost Development (Tables) 67: R35 Commercial Paper and Long-Term Debt (Tables) HTML 210K 70: R36 Income Taxes Income Tax (Tables) HTML 155K 42: R37 Shareholder's Equity Shareholder's Equity (Tables) HTML 43K 113: R38 Share-Based Compensation (Tables) HTML 117K 19: R39 Commitments and Contingencies Commitments and HTML 46K Contingencies (Tables) 60: R40 Segment Financial Information (Tables) HTML 292K 103: R41 Quarterly Financial Data (Unaudited) Quarterly HTML 80K Financial Data (Unaudited) (Tables) 40: R42 Schedule I Schedule I (Tables) HTML 196K 50: R43 Basis of Presentation Basis of Presentation Useful HTML 37K lives for property, equipment and capitalized software (Details) 54: R44 Basis of Presentation Basis of Presentation HTML 39K Medicare Part D (Details) 64: R45 Basis of Presentation Basis of Presentation HTML 93K Narrative (Details) 26: R46 Investments (Narrative) (Details) HTML 37K 46: R47 Investments (Short-Term and Long-Term Investments) HTML 91K (Details) 22: R48 Investments (Fair Value of Mortgage-Backed HTML 54K Securities by Credit Rating Origination) (Details) 102: R49 Investments (Amortized Cost and Fair Value of HTML 80K Available-for-Sale Debt Securities by Contractual Maturity) (Details) 39: R50 Investments (Amortized Cost and Fair Value of HTML 67K Held-To-Maturity Debt Securities by Contractual Maturity) (Details) 99: R51 Investments (Fair Value of Available-For-Sale HTML 63K Investments with Gross Unrealized Losses by Investment Type and Length of Time That Individual Securities Have Been in a Continuous Unrealized Loss Position) (Details) 43: R52 Investments (Net Realized Gains) (Details) HTML 55K 61: R53 Fair Value (Narrative) (Details) HTML 57K 21: R54 Fair Value (Financial Assets and Liabilities, HTML 76K Excluding AARP, Measured at Fair Value on a Recurring Basis) (Details) 24: R55 Fair Value (Financial Assets and Liabilities, HTML 58K Excluding AARP, Not Measured at Fair Value on a Recurring Basis) (Details) 53: R56 Fair Value (Reconciliation of Assets Measured at HTML 62K Fair Value on a Recurring Basis Using Level 3 Inputs) (Details) 31: R57 Fair Value (Assets and Liabilities measured at HTML 78K fair value on a recurring basis) (Details) 107: R58 Fair Value Fair Value Inputs Assets Quantitative HTML 43K Information (Details) 66: R59 Property, Equipment, and Capitalized Software HTML 41K Property, Equipment, and Capitalized Software Narrative (Details) 89: R60 Property, Equipment, and Capitalized Software HTML 63K Property, Equipment, and Capitalized Software table (Details) 45: R61 Goodwill and Intangible Assets Goodwill and HTML 90K Intangible Assets Narrative (Details) 48: R62 Goodwill and Intangible Assets Goodwill (Changes HTML 61K in the Carrying Amount of Goodwill by Reporting Segment) (Details) 96: R63 Goodwill and Intangible Assets Goodwill (Net HTML 62K Tangible Assets Acquired in Amil Acquisition) (Details) 93: R64 Goodwill and Intangible Assets Goodwill and Other HTML 54K Intangible Assets Gross carrying value, accumulated amortization and net carrying value of intangible assets (Details) 68: R65 Goodwill and Intangible Assets Goodwill and Other HTML 44K Intangible Assets Weighted-average useful lives assigned to finite-lived intangible assets acquired in business combinations (Details) 95: R66 Goodwill and Intangible Assets Goodwill and Other HTML 43K Intangible Assets Amortization Expense relating to Intangible Assets (Details) 44: R67 Medical Costs and Medical Costs Payable (Details) HTML 35K 72: R68 Medical Costs and Medical Costs Payable Medical HTML 58K Costs and Medical Costs Payable Rollforward (Details) 109: R69 Commercial Paper and Long-Term Debt (Narrative) HTML 96K (Details) 23: R70 Commercial Paper and Long-Term Debt (Commercial HTML 107K Paper and Long-Term Debt) (Details) 37: R71 Commercial Paper and Long-Term Debt Commercial HTML 51K Paper and Long-Term Debt Maturities of commercial paper and long-term debt (Details) 62: R72 Income Taxes Income Tax Narrative (Details) HTML 53K 29: R73 Income Taxes Income Taxes Components of the HTML 59K provision for income taxes (Details) 112: R74 Income Taxes Income Taxes Reconciliation of the HTML 81K tax provision at the U.S. Federal Statutory Rate to the provision for income taxes (Details) 41: R75 Income Taxes Income taxes components of deferred HTML 105K tax assets and liabilities (Details) 32: R76 Income Taxes Income Taxes Reconciliation of the HTML 53K beginning and ending amount of unrecognized tax benefits (Details) 36: R77 Shareholder's Equity Shareholder's Equity HTML 80K (Details) 25: R78 Share-Based Compensation (Narrative) (Details) HTML 40K 28: R79 Share-Based Compensation (Stock Option and SAR HTML 88K Activity) (Details) 80: R80 Share-Based Compensation (Restricted Share HTML 62K Activity) (Details) 34: R81 Share-Based Compensation Other Share-Based HTML 69K Compensation Data (Details) 108: R82 Share-Based Compensation (Share-Based Compensation HTML 52K Principal Fair Value Assumptions) (Details) 59: R83 Commitments and Contingencies (Details) HTML 41K 87: R84 Commitments and Contingencies Future Lease HTML 55K Payments (Details) 94: R85 Segment Financial Information (Details) HTML 147K 33: R86 Segment Financial Information Segment Financial HTML 42K Information (Narrative) (Details) 35: R87 Quarterly Financial Data (Unaudited) Quarterly HTML 62K Financial Data (Unaudited) (Details) 105: R88 Schedule I (Details) HTML 56K 30: R89 Schedule I Schedule I Condensed Balance Sheet HTML 117K (Details) 81: R90 Schedule I Schedule I Condensed Balanch Sheet HTML 59K (Parentheticals) (Details) 77: R91 Schedule I Schedule I Condensed Statment of HTML 90K Operations (Details) 97: R92 Schedule I Schedule I Statement of Cash Flows HTML 105K (Details) 76: R93 Schedule I Parent Commercial Paper and Long-Term HTML 48K Debt Maturities of commercial paper and long-term debt (Details) 111: XML IDEA XML File -- Filing Summary XML 178K 49: EXCEL IDEA Workbook of Financial Reports (.xls) XLS 4.30M 13: EX-101.INS XBRL Instance -- unh-20121231 XML 6.42M 15: EX-101.CAL XBRL Calculations -- unh-20121231_cal XML 305K 16: EX-101.DEF XBRL Definitions -- unh-20121231_def XML 1.35M 17: EX-101.LAB XBRL Labels -- unh-20121231_lab XML 2.60M 18: EX-101.PRE XBRL Presentations -- unh-20121231_pre XML 1.67M 14: EX-101.SCH XBRL Schema -- unh-20121231 XSD 274K 20: ZIP XBRL Zipped Folder -- 0000731766-13-000005-xbrl Zip 462K
UNH EX 31.1 12.31.2012 10K |
1. | I have reviewed this report on Form 10-K of UnitedHealth Group Incorporated (the “registrant”); |
2. | Based
on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The
registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries,
is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
c) | Evaluated the effectiveness of the
registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
d) | Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially
affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and |
5. | The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): |
a) | All
significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and |
b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. |
President and Chief Executive Officer | |
1. | I have reviewed this report on Form 10-K of UnitedHealth Group Incorporated (the “registrant”); |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements
made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The
registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries,
is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
c) | Evaluated the effectiveness of the
registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
d) | Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially
affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and |
5. | The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): |
a) | All
significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and |
b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. |
Executive Vice President and Chief Financial Officer of UnitedHealth Group and President of UnitedHealth Group Operations |
This ‘10-K’ Filing | Date | Other Filings | ||
---|---|---|---|---|
Filed as of: | 2/7/13 | |||
Filed on: | 2/6/13 | 4 | ||
For Period end: | 12/31/12 | 11-K, 3, ARS | ||
List all Filings |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/24/23 UnitedHealth Group Inc. 10-K 12/31/22 119:19M 2/15/22 UnitedHealth Group Inc. 10-K 12/31/21 113:19M 3/01/21 UnitedHealth Group Inc. 10-K 12/31/20 107:17M 5/22/13 SEC UPLOAD¶ 10/06/17 1:34K Unitedhealth Group Inc. 3/21/13 SEC UPLOAD¶ 10/06/17 1:161K Unitedhealth Group Inc. |